<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00657735</url>
  </required_header>
  <id_info>
    <org_study_id>BR-BIP-02</org_study_id>
    <nct_id>NCT00657735</nct_id>
  </id_info>
  <brief_title>Double Blind Randomized Controlled, H1 Coil In Subjects With Bipolar Depression</brief_title>
  <official_title>A Prospective Double Blind Randomized Controlled Trial To Explore The Tolerability, Safety And Efficacy Of The H1-Coil Deep Transcranial Magnetic Stimulation (TMS) In Subjects With Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shalvata Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brainsway</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shalvata Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to explore the efficacy and safety of H1-Coil deep brain rTMS in&#xD;
      subjects with bipolar depression , currently treated with mood stabilizer and previously&#xD;
      unsuccessfully treated with antidepressant medications&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in the Hamilton depression rating scale score</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical antidepressant remission at the end of the treatment, defined as exit Hamilton Depression Rating Scale &lt;10.</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deep TMS treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>inactive stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>H-Coil deep TMS</intervention_name>
    <description>20 daily deep rTMS treatments</description>
    <arm_group_label>1</arm_group_label>
    <other_name>H1 coil dTMS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham</intervention_name>
    <description>inactive treatment</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:• Outpatients&#xD;
&#xD;
          -  Diagnosed by two senior psychiatrists as suffering from bipolar depression (BP1, BP2)&#xD;
             episode according to DSM IV using the Structured Clinical Interview for DSM-4 (SCID),&#xD;
             with additional requirement of duration for the current episode ≥ 4 weeks and CGI ≥ 4.&#xD;
&#xD;
          -  Rating on HAM-D (17 items) &gt;20 and item 1 ≥2 at the screening visit.&#xD;
&#xD;
          -  Age: 18-65 years.&#xD;
&#xD;
          -  Gave informed consent for participation in the study.&#xD;
&#xD;
          -  Negative answers on safety screening questionnaire for transcranial magnetic&#xD;
             stimulation&#xD;
&#xD;
          -  Taking mood stabilizing medication (e.g., lithium) on an acceptable range of dosage&#xD;
             according to recent blood examination or antipsychotic medication as mood stabilizers&#xD;
             prescribed by their treating physician&#xD;
&#xD;
          -  According to the treating physician the patient is compliant in taking the&#xD;
             mood-stabilizing medication.&#xD;
&#xD;
          -  Medication resistance to at least two different antidepressant treatments, defined as&#xD;
             resistance to a minimum of 2 antidepressant drug trials of adequate dose and duration&#xD;
             in the current episode or previous episodes defined as a minimum level of 3 on the&#xD;
             ATHF per antidepressant drug-trial.&#xD;
&#xD;
          -  Patients who have not completed antidepressant trials of adequate dose and duration&#xD;
             due to intolerance to therapy may be included if they have demonstrated intolerance to&#xD;
             3 or more anti-depressant medications in the current or a previous episodes.&#xD;
&#xD;
          -  If currently taking antidepressant pharmacotherapy, must be clinically appropriate to&#xD;
             discontinue treatment with those agents.&#xD;
&#xD;
          -  Able to tolerate psychotropic medication washout and no psychotropics during the&#xD;
             H-coil deep brain rTMS other than benzodiazepine at equivalent dose of up to 3 mg&#xD;
             lorazepam every day.&#xD;
&#xD;
          -  Right hand dominance.&#xD;
&#xD;
        Exclusion Criteria:• Diagnosis as suffering from other diagnosis on axis 1 (like:&#xD;
        schizophrenia, geriatric depression).&#xD;
&#xD;
          -  Diagnosis as suffering from Severe Borderline Personality Disorder or hospitalized due&#xD;
             to exacerbation related to of borderline personality disorder.&#xD;
&#xD;
          -  Substantial suicidal risk as judged by the treating psychiatrist.&#xD;
&#xD;
          -  Attempted suicide in the past year.&#xD;
&#xD;
          -  Patients with a bipolar cycle of less than 30 days.&#xD;
&#xD;
          -  History of epilepsy or seizure in first degree relatives.&#xD;
&#xD;
          -  History of head injury.&#xD;
&#xD;
          -  History of any metal in the head (outside the mouth).&#xD;
&#xD;
          -  Known history of any metallic particles in the eye, implanted cardiac pacemaker or any&#xD;
             intracardiac lines, implanted neurostimulators, surgical clips or any medical pumps.&#xD;
&#xD;
          -  History of frequent or severe headaches.&#xD;
&#xD;
          -  History of migraine.&#xD;
&#xD;
          -  History of hearing loss.&#xD;
&#xD;
          -  Known history of cochlear implants&#xD;
&#xD;
          -  History of substance abuse within the past 6 months (except nicotine and caffeine) or&#xD;
             alcoholism&#xD;
&#xD;
          -  Pregnancy or not using a reliable method of birth control.&#xD;
&#xD;
          -  Unstable Systemic and metabolic disorders.&#xD;
&#xD;
          -  Unstable neurological or medical disease&#xD;
&#xD;
          -  Inadequate communication with the patient.&#xD;
&#xD;
          -  Under custodial care.&#xD;
&#xD;
          -  Participation in current clinical study or clinical study within 30 days prior to this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yechiel Levkovitz, MD</last_name>
    <email>ylevk@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oded Meiron, PhD student</last_name>
    <email>odedmei@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>shalvataMHC</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eiran v Harel, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>April 8, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <last_update_submitted>January 4, 2012</last_update_submitted>
  <last_update_submitted_qc>January 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bipolar</keyword>
  <keyword>depression</keyword>
  <keyword>prefrontal</keyword>
  <keyword>cortex</keyword>
  <keyword>antidepressant</keyword>
  <keyword>response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

